Matthias Imöhl,
Author Of 2 Presentations
INVASIVE PNEUMOCOCCAL DISEASE AMONG CHILDREN IN GERMANY, TEN YEARS AFTER PCV13 INTRODUCTION (ID 899)
Abstract
Background
Childhood PCV vaccination was generally recommended in Germany in 2006. Here, we present data on invasive pneumococcal disease (IPD) cases following PCV introduction.
Methods
IPD in children in Germany has been monitored since 1997. Isolates were serotyped using the Neufeld Quellung reaction.
Results
In 2018-2019, the GNRCS received 102 IPD isolates from children <2 years, of which 14 had PCV13 serotypes. Two of these were from unvaccinated children, four from incompletely vaccinated children. This represents a 34% reduction compared to 2005/2006 (n=154), but an increase since 2011-2012 (n=75). However, the PCV13 proportion has decreased from 88% prior to vaccine introduction (2005-2006), to 69% at the introduction of higher-valent vaccines (2009-2010), to 14% in 2018-2019. Future vaccines PCV15 (25%) and PCV20 (46%) would increase coverage considerably. Residual PCV13 serotypes in 2018/2019 were 3 (n=5), 19F (n=4), 19A (n=2) and 6A, 14, 23F (n=1, each). Among all three age groups (0-1y, 2-4y, 5-15y), serotypes 3, 19F and 19A persist. Among non-vaccine serotypes, 10A (n=17) and 23B (n=12) were most prevalent.
Conclusions
Ten years after the introduction of higher-valent vaccines, PCV13 serotypes have been reduced among children, but serotypes 3, 19F and 19A persist. Future vaccine formulation would considerably increase serotype coverage.
INVASIVE PNEUMOCOCCAL DISEASE AMONG ADULTS IN GERMANY, TEN YEARS AFTER PCV13 INTRODUCTION (ID 910)
Abstract
Background
Childhood PCV vaccination was generally recommended in Germany in 2006. Apart from a strong direct effect, herd protection effects among non-vaccinated children and adults were observed.
Methods
IPD in adults in Germany has been monitored since 1992. Isolates were serotyped using the Neufeld Quellung reaction.
Results
Prior to introduction of PCVs in infants, 45% of IPD serotypes found among adults were PCV7 types and 70% were PCV13 types. After the start of childhood vaccination, these percentages gradually reduced to 5% and 30% and remained stable in the past five seasons. In 2018-2019, prevalences were of serotypes 3, 4, 19F and 19A were 20.3%, 2.1%, 3.7% and 1.5% respectively. The prevalence of serotype 3 has reached its highest point ever since the introduction of PCVs. Among non-PCV13 types, serotypes 8 (14.0%), 22F (7.2%), 9N (6.4) and 12F (5.0%) were most prevalent. New PCV formulations would cover 38.7% (PCV15) and 65.2% (PCV20).
Conclusions
The herd protection effect of PCVs among adults has reached its limit. No herd protection effect was observed for serotype 3. The data implicate circulation of PCV13 serotypes among adults, which might only be interrupted by direct vaccination.